Wieczorek Aleksandra, Żebrowska Urszula, Ussowicz Marek, Sokół Agnieszka, Stypińska Marzena, Dembowska-Bagińska Bożenna, Pawińska-Wąsikowska Katarzyna, Balwierz Walentyna
Department of Pediatric Oncology and Hematology, Jagiellonian University Medical College, 30-663 Krakow, Poland.
Department of Pediatric Oncology and Hematology, University Children's Hospital of Krakow, 30-663 Krakow, Poland.
J Clin Med. 2023 Aug 11;12(16):5252. doi: 10.3390/jcm12165252.
Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including patients with relapsed/refractory (R/R) disease. However, the data on its use in real-world clinical practice is limited. We retrospectively reviewed the clinical records of 54 patients with HR-NB who received maintenance therapy with dinutuximab beta in first-line (37 patients) or R/R settings (17 patients) at three centers in Poland. Of the 37 patients who received first-line treatment, twenty-eight had a complete response, two had a partial response, three had progressive disease, and four relapsed at the end of treatment. The median overall survival (OS) was 24.37 months, and the three-year progression-free survival (PFS) and OS were 0.63 and 0.80, respectively. Of the 17 patients in the R/R group, 11 had a complete response, two had a partial response, one had stable disease, and three had progressive disease or relapsed at the end of treatment. The median OS was 33.1 months and the three-year PFS and OS were 0.75 and 0.86, respectively. Treatment was generally well tolerated, including in patients with co-morbidities and those who had experienced toxicities with previous therapies. These findings demonstrate that the use of dinutuximab beta is feasible and beneficial as a first-line or R/R treatment in routine clinical practice in Poland.
贝伐珠单抗已被批准用于高危神经母细胞瘤（HR-NB）患者的维持治疗，包括复发/难治性（R/R）疾病患者。然而，其在实际临床实践中的应用数据有限。我们回顾性分析了波兰三个中心54例接受贝伐珠单抗维持治疗的HR-NB患者的临床记录，其中37例为一线治疗，17例为R/R治疗。在接受一线治疗的37例患者中，28例完全缓解，2例部分缓解，3例疾病进展，4例在治疗结束时复发。中位总生存期（OS）为24.37个月，三年无进展生存期（PFS）和OS分别为0.63和0.80。在R/R组的17例患者中，11例完全缓解，2例部分缓解，1例病情稳定，3例疾病进展或在治疗结束时复发。中位OS为33.1个月，三年PFS和OS分别为0.75和0.86。治疗总体耐受性良好，包括合并症患者和既往治疗出现过毒性反应的患者。这些结果表明，在波兰的常规临床实践中，贝伐珠单抗作为一线或R/R治疗是可行且有益的。
